SHANGHAI, Jan. 8, 2026 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced that China's National Medical Products Administration (NMPA) has approved the New Drug Application for Serdexmethylphenidate Chloride and Dexmethylphenidate Hydrochloride Capsules...
Hence then, the article about ark biopharmaceutical receives china marketing authorization for aizhida for the treatment of adhd was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Ark Biopharmaceutical Receives China Marketing Authorization for Aizhida for the Treatment of ADHD )
Also on site :
- Ella Langley Honors Dolly Parton With Fiery ‘Jolene’ Cover: ‘Tonight’s Show Didn’t Feel Right Without Doing Something Like This’
- 1974 Hit, Named Among ‘Soul Train’s Best Musical Moments,’ Is Still a ‘Mind-Blowing’ Performance Over 5 Decades Later
- El provocador británico Milo Yiannopoulos se enfrenta a la deportación tras una trayectoria en la ultraderecha estadounidense